News
Op-ed: Congress must act now to extend this lifeline for New York biotech
Overview
The op-ed highlights the importance of the SBIR and STTR programs, which fund high-risk biotech research and bridge the early-stage investment gap that private capital often won’t cover. These programs have enabled major breakthroughs in research and development while generating strong economic returns, especially in New York’s fast-growing life sciences sector.
In This Article
NewYorkBIO urges the Senate to reauthorize SBIR to protect both innovation and patient progress.
